Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To establish the maximum tolerated dose (MTD) of irinotecan when administered by an intra-peritoneal route every three weeks.
Syma Iqbal, M.D.
U.S.C. / Norris Comprehensive Cancer Center
United States: Food and Drug Administration
|U.S.C. / Norris Comprehensive Cancer Center||Los Angeles, California 90033|